Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients
作者： R.H.G.P. Arends , M.A. Karsdal , K.M. Verburg , C.R. West , A.C. Bay-Jensen
DOI: 10.1016/J.JOCA.2017.01.006
关键词:
摘要: Summary Objective Establish a biomarker panel associated with all-cause total joint replacement (TJR) through identification of patients osteoarthritis (OA) who do or not progress to TJR and investigate effects nonsteroidal anti-inflammatory drugs (NSAIDs). Design Serum samples from enrolled in phase III trials tanezumab experienced ( n = 174) matched did = 321) were analyzed for bone, cartilage, soft tissue, inflammation markers. Classification Regression Tree (CART) analysis was used identify phenotypes TJR. Results At baseline, combinations use NSAIDs before starting during treatment Conclusions Although validation on other cohorts is necessary, biomarkers may assist identifying will need The profiles suggest NSAID increases importance bone metabolism pathology.
oarsijournal.com参考文章(44)
Anne C. Bay-Jensen, Morten A. Karsdal, Efstathios Vassiliadis, Stephanie Wichuk, Kathrine Marcher-Mikkelsen, Rik Lories, Claus Christiansen, Walter P. Maksymowych, Circulating Citrullinated Vimentin Fragments Reflect Disease Burden in Ankylosing Spondylitis and Have Prognostic Capacity for Radiographic Progression Arthritis & Rheumatism. ,vol. 65, pp. 972- 980 ,(2013) , 10.1002/ART.37843
Terry M. Therneau, Elizabeth J. Atkinson, An Introduction to Recursive Partitioning Using the RPART Routines ,(2015)
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith, Christine R. West, Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis & Rheumatism. ,vol. 65, pp. 1795- 1803 ,(2013) , 10.1002/ART.37950
Richard A Olshen, Charles J Stone, Leo Breiman, Jerome H Friedman, Classification and regression trees ,(1983)
Anne-Christine Bay-Jensen, Bodil Cecilie Sondergaard, Claus Christiansen, Morten A. Karsdal, Suzi Høgh Madsen, Per Qvist, Biochemical Markers of Joint Tissue Turnover ASSAY and Drug Development Technologies. ,vol. 8, pp. 118- 124 ,(2010) , 10.1089/ADT.2009.0199
M. A. Karsdal, H. Krarup, J. M. B. Sand, P. B. Christensen, J. Gerstoft, D. J. Leeming, N. Weis, O. B. Schaffalitzky de Muckadell, A. Krag, Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Alimentary Pharmacology & Therapeutics. ,vol. 40, pp. 233- 249 ,(2014) , 10.1111/APT.12820
Piet Geusens, Pieter J. Emans, Joost J.A. de Jong, Joop van den Bergh, NSAIDs and fracture healing Current Opinion in Rheumatology. ,vol. 25, pp. 524- 531 ,(2013) , 10.1097/BOR.0B013E32836200B8
P. Vestergaard, P. Hermann, J.-E. B. Jensen, P. Eiken, L. Mosekilde, Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS) Osteoporosis International. ,vol. 23, pp. 1255- 1265 ,(2012) , 10.1007/S00198-011-1692-0
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith, Christine R. West, Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. The Journal of Pain. ,vol. 13, pp. 790- 798 ,(2012) , 10.1016/J.JPAIN.2012.05.006
Steven B Abramson, Mukundan Attur, Yusuf Yazici, Prospects for disease modification in osteoarthritis Nature Reviews Rheumatology. ,vol. 2, pp. 304- 312 ,(2006) , 10.1038/NCPRHEUM0193